Form 4: Pulse Biosciences Director Granted 54,134 Stock Options

Pulse Biosciences Director Mahkam Zanganeh was granted 54,134 stock options with an exercise price of $16.16, vesting over one year.

Summary

• Mahkam Zanganeh, a Director of Pulse Biosciences, Inc. (PLSE), was granted two tranches of stock options.
• The first tranche consists of 30,000 stock options with an exercise price of $16.16.
• These 30,000 options will vest in equal monthly installments over a one-year period, beginning September 15, 2025.
• The second tranche consists of 24,134 stock options, also with an exercise price of $16.16.
• These 24,134 options will vest in equal quarterly installments over a one-year period, beginning September 5, 2025.
• Both tranches of options have an expiration date of August 15, 2035.
• The total number of stock options granted to the Director is 54,134.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates continued commitment from a director through an equity grant, aligning their interests with the company's long-term performance. It's a standard, expected event for a public company.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and retention.
• The vesting schedule, tied to continued service, promotes stability in the board of directors.

Risks

• The value of the stock options is dependent on the future stock price of Pulse Biosciences exceeding the exercise price of $16.16.
• The vesting of options is contingent on the Director's continued service, meaning unvested options would be forfeited upon departure.

Future Outlook

The future outlook for the granted options is tied to the company's stock performance relative to the $16.16 exercise price. The vesting schedules indicate a commitment to the Director's continued service over the next year, aligning their incentives with future company growth.

Management Comments

• The filing was signed by Kenneth B. Stratton, as Attorney-in-Fact for Mahkam Zanganeh.

Industry Context

This Form 4 filing is a routine disclosure of an equity grant to a director, common practice in publicly traded companies across all industries to incentivize and retain key personnel. It reflects standard corporate governance and compensation practices within the biotechnology or medical device sector, where Pulse Biosciences operates.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across industries, including biotechnology and medical devices, to align director interests with shareholder value.
• The exercise price being at or above the market price on the grant date (implied by the nature of a typical option grant) is a common practice for incentive options.
• One-year vesting schedules, whether monthly or quarterly, are typical for director equity grants, balancing immediate incentive with long-term retention.

Related Party Transactions

• The grant of stock options to a director is a transaction with a related party (company director) as part of their compensation.

Stakeholder Impact

• Shareholders: The grant aligns the Director's interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated, but it reinforces the company's compensation structure for leadership.
• Management: The grant to a director reinforces the board's commitment and oversight.

Next Steps

• The granted stock options will begin vesting in monthly installments starting September 15, 2025, for 30,000 shares.
• The granted stock options will begin vesting in quarterly installments starting September 5, 2025, for 24,134 shares.
• The Director's continued service is required for the options to vest.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice and does not typically indicate a significant change in the company's fundamental outlook or operations. While it aligns director incentives with shareholder interests, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should 'hold' and consider this information in the broader context of the company's financial performance, strategic initiatives, and market conditions.

Keywords

Pulse Biosciences, PLSE, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Executive Compensation, Vesting Schedule